Fig 2.

rPVM-GFPgp33-infected cells express gp33 in vitro and in vivo. (A) CFSE proliferation assay. RAW309Cr1 macrophages were infected with rPVM-1 (left), loaded with gp33 peptide (middle), or infected with rPVM-GFPgp33 (right) and incubated for 6 days with CFSE-labeled P14 spleen cells. CFSE dilution of Vα2-positive CD3⁺ CD8⁺ T cells is shown. Dot plots are representative of two independent experiments. (B and C) C57BL/6 mice were infected with 100 to 200 PFU of rPVM-GFPgp33 and at the indicated time points, BAL fluid cells were analyzed. (B) Percentage of gp33 dimer-positive cells among total CD3⁺ CD8⁺ T cells. Data were pooled from two independent experiments. (C) Percentage of cells producing IFN-γ after gp33 peptide stimulation among total CD3⁺ CD8⁺ lymphocytes. Data were pooled from two independent experiments. (D) LCMV-immune or naive C57BL/6 mice were intranasally infected with 5,000 PFU of rPVM-GFPgp33 or rPVM-GFP. Seven days after infection, lung viral titers were determined by plaque assay. n.s., not significant; ***, P < 0.001.